Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
>
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
Read also
NewAmsterdam Pharma Starts Phase 2b Trial of Obicetrapib in Alzheimer’s
NewAmsterdam Pharma has dosed its first patient in the Phase 2b SPINOZA trial to evaluate Obicetrapib in adults with preclinical Alzheimer’s disease.
Clinical Trials Struggle to Recruit Undiagnosed Patients Without Coverage
Clinical trials face major operational challenges in recruiting patients with rare, undiagnosed conditions due to a lack of diagnostic testing coverage.
Immix’s NXC-201 achieves 89% complete response rate in AL amyloidosis trial
Immix Biopharma announced an 89% complete response rate for its BCMA-targeted CAR-T cell therapy NXC-201 in a Phase 2 trial for relapsed AL amyloidosis.
FDA recalls thousands more bottles of blood pressure meds due to issues
The FDA has issued a second recall this year for thousands of bottles of Chlorthalidone blood pressure tablets because the pills do not dissolve properly.
